pubmed_result_abstract-annotated_individual.json

{"id": 2, "text": "The BRAF inhibitor dabrafenib (Tafinlar(®)) and the MEK inhibitor trametinib (Mekinist(®)) are indicated, as monotherapy or in combination with each other, for the treatment of patients with unresectable or metastatic melanoma with a BRAF (V600) mutation.", "annotations": [{"label": 7, "start_offset": 4, "end_offset": 8, "user": 1}, {"label": 8, "start_offset": 19, "end_offset": 29, "user": 1}, {"label": 9, "start_offset": 53, "end_offset": 56, "user": 1}, {"label": 8, "start_offset": 67, "end_offset": 77, "user": 1}, {"label": 10, "start_offset": 220, "end_offset": 228, "user": 1}, {"label": 7, "start_offset": 236, "end_offset": 240, "user": 1}, {"label": 11, "start_offset": 242, "end_offset": 246, "user": 1}], "meta": {}}
{"id": 4, "text": "Dabrafenib plus trametinib significantly prolonged progression-free survival (PFS) and overall survival (OS), improved objective response rates (ORRs) and preserved health-related quality of life (HR-QOL) to a greater extent than dabrafenib (in the double-blind COMBI-d study) and vemurafenib (in the open-label COMBI-v study) in two large, randomized, phase III studies in treatment-naïve patients with unresectable or metastatic melanoma with BRAF (V600E/K) mutation.", "annotations": [{"label": 8, "start_offset": 0, "end_offset": 10, "user": 1}, {"label": 8, "start_offset": 16, "end_offset": 26, "user": 1}, {"label": 8, "start_offset": 230, "end_offset": 241, "user": 1}, {"label": 10, "start_offset": 432, "end_offset": 441, "user": 1}, {"label": 7, "start_offset": 446, "end_offset": 450, "user": 1}, {"label": 11, "start_offset": 452, "end_offset": 459, "user": 1}], "meta": {}}
{"id": 5, "text": "Limited treatment benefit with the combination was also seen in patients who had progressed on prior BRAF inhibitor therapy, as indicated by ORRs of ≤ 15 % and stable disease in ≤ 50 % of patients in small phase I and II studies.Limited treatment benefit with the combination was also seen in patients who had progressed on prior BRAF inhibitor therapy, as indicated by ORRs of ≤ 15 % and stable disease in ≤ 50 % of patients in small phase I and II studies.", "annotations": [{"label": 7, "start_offset": 101, "end_offset": 106, "user": 1}, {"label": 7, "start_offset": 336, "end_offset": 341, "user": 1}], "meta": {}}
{"id": 6, "text": "Combination therapy did not increase overall toxicity relative to dabrafenib or vemurafenib monotherapy, with most adverse events (AEs) mild or moderate in severity and generally manageable.", "annotations": [{"label": 8, "start_offset": 66, "end_offset": 77, "user": 1}, {"label": 8, "start_offset": 80, "end_offset": 92, "user": 1}], "meta": {}}
{"id": 9, "text": "This article reviews the therapeutic efficacy and tolerability of combination treatment with dabrafenib and trametinib in this indication and summarizes relevant pharmacological data.", "annotations": [{"label": 8, "start_offset": 93, "end_offset": 104, "user": 1}, {"label": 8, "start_offset": 108, "end_offset": 119, "user": 1}], "meta": {}}
{"id": 10, "text": "Fewer skin-related AEs (e.g. cutaneous malignancies, hyperkeratinosis and hand-foot syndrome) were reported with combination therapy than with dabrafenib or vemurafenib, probably because of reduced paradoxical activation of the MAPK pathway.", "annotations": [{"label": 8, "start_offset": 143, "end_offset": 154, "user": 1}, {"label": 8, "start_offset": 157, "end_offset": 168, "user": 1}], "meta": {}}
{"id": 11, "text": "Thus, dabrafenib plus trametinib provides an important treatment option for patients with BRAF (V600) mutation-positive unresectable or metastatic melanoma.", "annotations": [{"label": 8, "start_offset": 6, "end_offset": 17, "user": 1}, {"label": 8, "start_offset": 22, "end_offset": 33, "user": 1}, {"label": 7, "start_offset": 90, "end_offset": 95, "user": 1}, {"label": 11, "start_offset": 96, "end_offset": 100, "user": 1}, {"label": 10, "start_offset": 147, "end_offset": 155, "user": 1}], "meta": {}}